Q4 2025 ICU Medical Inc Earnings Call Transcript
Key Points
- ICU Medical Inc (ICUI) reported a strong Q4 revenue of $536 million, achieving 2% organic growth and maintaining gross margins above 40%.
- The Consumables business experienced a record quarter with 6% reported growth and 5% organic growth, driven by high-single-digit growth in infusion consumables, oncology, and tracheostomy product lines.
- The company successfully closed the FDA warning letter received by Smiths Medical, validating their operational improvements and opening up more strategic choices.
- ICU Medical Inc (ICUI) has completed the manufacturing integration of two large legacy Smiths Medical sites, which is expected to lead to future synergies and cost savings.
- The company has a strong cash generation, allowing it to repay additional principal, reducing net debt to just below $1 billion.
- The reported revenue showed a decline of 14% due to the deconsolidation of the IV Solutions business following the creation of the Otsuka-ICU Medical JV.
- Adjusted EBITDA for Q4 decreased by 7% year-over-year, impacted by the deconsolidation of the IV Solutions business and tariffs, resulting in a $25 million negative impact.
- Vital Care segment saw a 6% organic decrease and a 35% reported decrease due to the deconsolidation of IV Solutions, impacting overall company growth rates.
- The company faces ongoing challenges with tariffs, which are expected to impact gross margins by approximately 2% of revenue in 2026.
- Despite improvements, the integration of Smiths Medical has been bumpier and taken longer than expected, with the 2026 EBITDA guidance still short of the original $500 million target.
Good day, and welcome to the ICU Medical, Inc., fourth-quarter 2025 earnings conference call. (Operator Instructions) Please note today's event is being recorded.
I'd like to now turn the conference over to John Mills. Please go ahead, sir.
Good afternoon, everyone. Thank you for joining us to discuss ICU Medical's financial results for the fourth quarter and full year of 2025. On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman; and Brian Bonnell, Chief Financial Officer.
We want to let everyone know that we have a presentation accompanying today's prepared remarks. To view the presentation, please go to our Investor page and click on the event calendar and will be under the fourth-quarter 2025 events.
Before we start our prepared remarks, I want to touch upon any forward-looking statements made during the call, including beliefs and expectations about the company's future results. Please be aware they are based on the best available information to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
